Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy.
about
Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indicationsOld drug, new trick: repurposing metformin for gynecologic cancers?Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer RiskNew classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical careThe search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancerThe metabolic state of cancer stem cells-a valid target for cancer therapy?Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy.High Glucose-Mediated STAT3 Activation in Endometrial Cancer Is Inhibited by Metformin: Therapeutic Implications for Endometrial Cancer.In Vitro and In Vivo Modulation of Alternative Splicing by the Biguanide MetforminAMPK and Endothelial Nitric Oxide Synthase Signaling Regulates K-Ras Plasma Membrane Interactions via Cyclic GMP-Dependent Protein Kinase 2.Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance)Metformin inhibits estrogen-dependent endometrial cancer cell growth by activating the AMPK-FOXO1 signal pathway.Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-survivin pathway.Systematic Analysis of Endometrial Cancer-Associated Hub Proteins Based on Text MiningTargeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials.Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 statusDeciphering lipid codes: K-Ras as a paradigm.Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study.Lean Body Weight and Metformin Are Insufficient to Prevent Endometrial Hyperplasia in Mice Harboring Inactivating Mutations in PTEN.Metformin as a Therapeutic Target in Endometrial Cancers
P2860
Q22242884-73B87B89-67CE-48F8-895E-DF3A53C6650CQ27010558-4A472D82-D6CA-4BB7-B6C5-9A2CAEEEFB9CQ28072521-BBAC941C-2F34-4E68-921F-8D9953C0F7E3Q28078792-ABFAEB96-BF98-41C2-AE01-1D55D4FEE550Q33689293-0484BE17-12BA-4B2F-8B58-D1EE17EBB194Q35118801-8BFCCF1F-933A-4CE7-99EC-27F5D4121DE3Q35176084-D9402605-68BE-419E-9AD2-3B5118831AB5Q35898773-93C40E0D-1245-4E4D-A8D1-9E01956EDE70Q36257678-BC36C0E8-B037-4FBB-B37B-F42B7396FADFQ36928108-5AB334A2-03E0-4FC8-8738-DCBEC7406955Q37448013-5F589E5F-436E-4535-A738-2A0724CA9813Q37496645-2B115C41-2752-4154-8267-D3BBBAAA3B2CQ37544382-2B5C0E27-2A5C-4C54-8223-1E71E6BF8BB3Q37733068-AE04FE6F-F168-45F2-9BBC-1EB058DF15AEQ40543038-71FF7AC9-7930-4359-B2B6-7C441F2942CAQ41339882-B1BE0171-5ABF-48B4-A9D3-96A514BDC4EFQ41708717-9D92FD85-D4EF-4329-AB62-095F183453CDQ46264996-7C1D61BB-8CB8-4659-A8E4-B7ED765FC46FQ46464670-06956B9F-FDCF-461E-9C81-031B9EB4B066Q47252413-5CF9B23D-BA1E-4546-9715-2BC20CA04ADCQ58698115-B4037C88-F19D-4296-B2D5-B96F7D732DEF
P2860
Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Another surprise from Metformi ...... al cancer response to therapy.
@en
Another surprise from Metformi ...... al cancer response to therapy.
@nl
type
label
Another surprise from Metformi ...... al cancer response to therapy.
@en
Another surprise from Metformi ...... al cancer response to therapy.
@nl
prefLabel
Another surprise from Metformi ...... al cancer response to therapy.
@en
Another surprise from Metformi ...... al cancer response to therapy.
@nl
P2093
P2860
P1476
Another surprise from Metformi ...... ial cancer response to therapy
@en
P2093
David A Iglesias
Dharini van der Hoeven
Jennifer Burzawa
John F Hancock
Joseph Celestino
Karen H Lu
Melinda S Yates
Ngai Na Co
Qian Zhang
Rosemarie Schmandt
P2860
P304
P356
10.1158/1535-7163.MCT-13-0439
P577
2013-09-27T00:00:00Z